By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



245 First Street - 18th Floor
Suite 1806
Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-444-8416 Fax: 617- 444-8405

Genfit is a biopharmaceutical company, listed on Alternext by Euronext™ Paris (ALGFT - FR0004163111) with headquarters in Lille, France and a US subsidiary in Cambridge, Massachusetts.

Through its world-renowned scientific expertise, particularly in the field of nuclear receptors, Genfit’s research efforts are focused on the discovery and development of new treatments mainly in the growing therapeutic areas of Cardiometabolic and Neurodegenerative disorders, such as prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity, and Alzheimer’s. Genfit uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments to address these major public health problems and their unmet medical needs.

Genfit has an original business model built on both proprietary internal programs and a strong track record of partner-supported programs and collaborations. This strategy allows the company to efficiently manage the risks associated with the internal programs, and at the same time build value for its shareholders. Genfit, on its own or in collaboration with its major pharmaceutical partners, has thus created a rich and diversified pipeline of drug candidates in pre-clinical and clinical development, as well as a broad intellectual property portfolio.

Genfit’s strong portfolio of therapeutic products, tools, and clinical biomarkers, together with its scientific expertise, have made the Company into a European biotechnology leader.

Parc Eurasanté – Lille Metropole
885 Avenue Eugene Avinee
59120 Loos
Tel : +33 (0)3 2016 4000
Fax : +33 (0)3 2016 4001

Key Statistics

Ownership: Public

Web Site: GENFIT
Employees: 125 (Scientists: 100)
Symbol: ALGFT

Company News
GENFIT (ALGFT) Announces The Acceptance Of Two New Abstracts, Including One To Be Presented In An Oral Session At The 2016 AASLD Meeting 10/20/2016 12:25:04 PM
GENFIT (ALGFT): New Scientific Data To Be Presented During Next AASLD Annual Meeting; Strong Involvement In The First-Ever NASH-TAG Conference 10/3/2016 9:10:15 AM
GENFIT (ALGFT) Is Filing For IND Submission For New Indication Of Elafibranor In Primary Biliary Cholangitis (PBC) 9/28/2016 12:41:03 PM
GENFIT (ALGFT): Successful Identification Of ROR?t Inverse Agonists As Candidates For Regulatory Pre-IND Studies 9/23/2016 8:51:06 AM
GENFIT (ALGFT): Significant Milestones Achieved Under A New Qualification Program Of Proprietary miRNAs And Algorithms For A Non-Invasive NASH Diagnostic 9/20/2016 9:27:15 AM
GENFIT (ALGFT): First Quarter 2016 Financial Information 4/26/2016 2:15:30 PM
GENFIT (ALGFT) To Begin Elafibranor Clinical Program In PBC 3/31/2016 11:02:30 AM
GENFIT (ALGFT): Presentations At EASL/ILC 2016 Highlight Progress In NASH Treatment, Biomarker Diagnostics, And Programs Targeting Fibrotic Diseases 3/30/2016 8:59:57 AM
GENFIT (ALGFT) To Host R&D Event On March 31, 2016 3/29/2016 9:22:09 AM
Data From Phase 2b Trial Of GENFIT (ALGFT)'s Elafibranor Published In Gastroenterology 2/11/2016 3:09:58 PM